Related Experiment Video
Updated: May 15, 2026
10:21
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond
Mohammad Salem1, Jakob Benedict Seidelin, Gerhard Rogler
1Department of Gastroenterology D, Medical Section, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark.
Cellular and Molecular Life Sciences : CMLS
|January 1, 2013
Summary
Muramyl dipeptide (MDP), a bacterial compound, significantly contributes to Crohn's disease (CD) pathogenesis by activating inflammatory pathways. Understanding MDP signaling, including NOD2 interactions, is crucial for developing new CD therapies.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- Crohn's disease (CD) is a chronic inflammatory bowel disease with complex etiology.
- Genetic, microbiological, and immunological factors contribute to CD development.
Purpose of the Study:
- To review the role of muramyl dipeptide (MDP) in activating inflammatory pathways in CD pathogenesis.
- To highlight the significance of MDP signaling and its mediators, such as NOD2, in CD.
Main Methods:
- Literature review focusing on the role of MDP in inflammatory bowel disease.
- Analysis of immunological responses triggered by MDP in the intestinal system.
- Examination of the association between alterations in MDP response mediators and CD.
Main Results:
- MDP, present in various bacteria, elicits significant immunological responses in the gut.
- Alterations in MDP signaling mediators, including nucleotide oligomerization domain 2 (NOD2), are linked to CD.
- Both NOD2-dependent and independent MDP effects contribute to CD pathogenesis.
Conclusions:
- MDP signaling plays a critical role in the pathogenesis of Crohn's disease.
- Modulating MDP pathways offers potential for novel therapeutic strategies for CD.
- Further research into NOD2 and non-NOD2 mediated MDP effects is warranted for therapeutic development.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...